Scarica l'app Stockscreener
2.69
2.18%
-0.06
Dopo l'orario di chiusura:
2.69
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.75
Aprire:
$2.61
Volume 24 ore:
2.51M
Relative Volume:
2.26
Capitalizzazione di mercato:
$182.94M
Reddito:
$488.00K
Utile/perdita netta:
$-41.44M
Rapporto P/E:
-2.8925
EPS:
-0.93
Flusso di cassa netto:
$-31.47M
1 W Prestazione:
-14.33%
1M Prestazione:
-30.22%
6M Prestazione:
+0.75%
1 anno Prestazione:
-53.94%
Intervallo 1D:
$2.50
$2.87
Intervallo di 1 settimana:
$2.50
$3.13
Portata 52W:
$2.01
$6.27
Cardiff Oncology Inc Stock (CRDF) Company Profile
Nome
Cardiff Oncology Inc
Settore
Industria
Telefono
858-952-7570
Indirizzo
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Confronta CRDF con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
2.69 | 182.94M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-06 | Iniziato | Craig Hallum | Buy |
| 2022-01-05 | Iniziato | William Blair | Outperform |
| 2021-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2021-08-09 | Ripresa | Maxim Group | Buy |
| 2020-10-22 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-08 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Cardiff Oncology Inc Borsa (CRDF) Ultime notizie
HighTower Advisors LLC Grows Position in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Lucid Capital Markets sets $14 target on Cardiff Oncology stock By Investing.com - Investing.com Canada
Cardiff Oncology Inc (CRDF) Has A Gold Mine On Its Hands - stocksregister.com
Charles Schwab Investment Management Inc. Sells 19,629 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Is Cardiff Oncology, Inc. (CRDF) The Hot Biotech Stock Under $5? - Insider Monkey
Bank of New York Mellon Corp Increases Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
10 Hot Biotech Stocks Under $5 - Insider Monkey
Is Cardiff Oncology 15% bump due to positive clinical trials or a short squeeze? - Mugglehead
Cardiff Oncology Inc (CRDF) Q4 2024 Earnings Report Preview: Wha - GuruFocus.com
Future Industry Growth Of Metastatic Prostate Cancer Market - openPR
Rhumbline Advisers Buys 10,290 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Why the Global Cancer Market Could Surpass $900 Billion-And the Stocks Leading the Charge - The Malaysian Reserve
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - Canada NewsWire
Cardiff Oncology’s Earnings Call: Optimism Amid Challenges - MSN
Financial Review: Kymera Therapeutics (NASDAQ:KYMR) vs. Cardiff Oncology (NASDAQ:CRDF) - Defense World
All You Need to Know About Cardiff Oncology (CRDF) Rating Upgrade to Buy - Nasdaq
Q1 Earnings Forecast for CRDF Issued By William Blair - Defense World
Cardiff Oncology (NASDAQ:CRDF) Price Target Raised to $17.00 - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Cardiff Oncology (NASDAQ:CRDF) Stock - MarketBeat
Cardiff Oncology Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Cardiff Oncology (NASDAQ:CRDF) Announces Quarterly Earnings Results - MarketBeat
Cardiff Oncology plans mixed shelf offering - MSN
Cardiff Oncology, Inc. (NASDAQ:CRDF) Q4 2024 Earnings Call Transcript - Insider Monkey
Cardiff Oncology Inc (CRDF) Q4 2024 Earnings Call Highlights: Financial Fortification and ... - Yahoo Finance
Cardiff Oncology Highlights Progress in Cancer Trials - TipRanks
Cardiff Oncology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings call transcript: Cardiff Oncology Q4 2024 highlights strategic advances - Investing.com
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - The Manila Times
Cardiff Oncology Reports Positive Initial Efficacy Data for Onvansertib in Metastatic Colorectal Cancer and Secures $40 Million Financing - Nasdaq
Cardiff Oncology, Inc. SEC 10-K Report - TradingView
Cardiff Oncology Inc (CRDF) Q4 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Cardiff Oncology Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Cardiff Oncology to Present at Upcoming Investor Conferences - The Manila Times
Can Cardiff Oncology's New Colorectal Cancer Approach Transform Treatment? CEO to Reveal Strategy - StockTitan
Critical Contrast: Cardiff Oncology (NASDAQ:CRDF) versus Vir Biotechnology (NASDAQ:VIR) - Defense World
Cardiff Oncology (CRDF) to Release Earnings on Thursday - Defense World
Cardiff Oncology (CRDF) Projected to Post Earnings on Thursday - MarketBeat
Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update - The Manila Times
Can Cardiff Oncology's Q4 Earnings Reveal New Cancer Drug Progress? - StockTitan
Bullish Cardiff Oncology Insiders Rewarded As Their Investment Rises To US$1.81m - Yahoo Finance
Cardiff Oncology, Inc. (NASDAQ:CRDF) Sees Significant Growth in Short Interest - MarketBeat
Taking on analysts’ expectations and winning: Cardiff Oncology Inc (CRDF) - SETE News
Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib (NASDAQ:CRDF) - Seeking Alpha
Cardiff Oncology, Inc. (NASDAQ:CRDF) Sees Significant Increase in Short Interest - Defense World
Cardiff Oncology Inc Azioni (CRDF) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):